Surfing NASH offered on-site coverage of EASL Congress 2023 in two separate real-time reviews. This conversation features the final session exploring the first three days of the meeting with Ian Rowe, Michael Betel, Jörn Schattenberg and Roger Green.

The focus of the group ranges from discussion around the FGF-21 agents efruxifermin and pegozafermin to the results of two major screening trials emerging from respected NAIL-NIT data. Finally, they discuss the broad rubric of AI and the many widely varying technologies that are currently described as utlizing AI. Roger’s closing question calls attention to a few additional major impressions from the event yet to be elaborated on in the preceding conversations. The panelist responses ranged from comments around the state of public health on Ukrainian frontlines, a different take on the NAIL-NIT presentation and lastly interest in the American Diabetes Association meeting taking place simultaneously in San Diego.

For a variety of reasons the entire community looks forward to this meeting with an unprecedented sense of intensity and excitement. These seven conversations suggest that the actual event met or exceeded such high expectations – listen on to learn how and why and stay tuned for Part 2 of this exclusive coverage. If you have any question or interests around EASL Congress, we kindly ask that you submit reviews wherever you download the discourse. Alternatively, you can write to us directly at questions@SurfingNASH.com.

Stay Safe and Surf On!